CellPoint B.V.
https://cellpoint.bio/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CellPoint B.V.
Galapagos Expands Point-Of-Care CAR-T Study To The US
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.
J.P. Morgan Day Two: Playing Up Potential In The Year Ahead
Daily notebook from the J.P. Morgan Healthcare Conference: Small and mid-size companies take the stage to lay out their guidance for the year, while big pharma is pushed on strategy and business development. Updates from GSK, Mirati, Sarepta, Amgen and US FDA commissioner Robert Califf.
Looking To Learn From Past Failures, Galapagos Pivots To Immunology And CAR-T
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.
Company Information
- Industry
- Biotechnology
- Contract Research Organization-CRO
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice